通货膨胀调整后初次全髋翻修术的医保报销趋势:2002至2019年显著下降
该研究基于美国CMS医师费用表,分析2002至2019年因感染(rTHA-I)和无菌并发症(rTHA-A)行翻修全髋关节置换术的医保报销趋势,经通胀调整至2019年美元后,rTHA-A各术式报销下降约27%,rTHA-I两阶段报销分别下降18.74%和24.45%,且rTHA-I总下降额显著大于rTHA-A。
要点
- 通胀调整后rTHA-A各术式报销下降约27%。
- 两阶段rTHA-I报销分别下降18.74%和24.45%。
- rTHA-I总报销下降额显著大于rTHA-A。
核心结论
- 2002至2019年rTHA-I和rTHA-A的医师费用报销均持续贬值,且rTHA-I的下降幅度更大。
研究设计与样本
- 利用CMS医师费用表查询工具提取2002至2019年1期和2期rTHA-I及1期rTHA-A的报销数据,按AAOS编码参考指南分组CPT码,用消费者价格指数调整为2019年美元后计算累计和年均百分比变化。
主要发现
- rTHA-A股骨组件翻修报销从2002年$2,209.11降至2019年$1,603.20,平均下降27.26%±3.57%。
- rTHA-A髋臼组件翻修报销从$2,130.55降至$1,542.91,平均下降27.41%±3.57%。
- rTHA-A全组件翻修报销从$2,775.53降至$2,007.61,平均下降27.50%±2.56%。
- 2期rTHA-I取出阶段报销从$2,063.36降至$1,673.36,平均下降18.74%±3.87%。
- 2期rTHA-I再植入阶段报销从$2,328.79降至$1,755.45,平均下降24.45%±3.69%。
关键数值与推荐
- rTHA-I总医师费用下降$1,020.64±$233.72,显著大于rTHA-A的$580.72±$107.22(p<0.00001)。
- 证据等级为经济与决策分析Level IV。
临床怎么用
- 骨科医生应了解rTHA-I和rTHA-A报销持续下降的趋势,可能影响开展此类手术的积极性。
局限性
- 本研究为经济与决策分析(Level IV),仅基于CMS医师费用表数据,未涉及其他支付方或实际成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Investigations into reimbursement trends for primary and revision arthroplasty procedures have demonstrated a steady decline over the past several years. Revision total hip arthroplasty (rTHA) due to infection (rTHA-I) has been associated with higher resource utilization and complexity, but long-term inflation-adjusted data have yet to be compared between rTHA-I and rTHA due to aseptic complications (rTHA-A). The present study was performed to analyze temporal reimbursement trends regarding rTHA-I procedures compared with those for rTHA-A procedures. METHODS: The Centers for Medicare & Medicaid Services (CMS) Physician Fee Schedule Look-Up Tool was used to extract Medicare reimbursements associated with 1-stage and 2-stage rTHA-I as well as 1-stage rTHA-A procedures from 2002 to 2019. Current Procedural Terminology (CPT) codes for rTHA were grouped according to the American Academy of Orthopaedic Surgeons coding reference guide. Monetary values were adjusted for inflation using the consumer price index (U.S. Bureau of Labor Statistics; reported as 2019 U.S. dollars) and used to calculate the cumulative and average annual percent changes in reimbursement. RESULTS: Following inflation adjustment, the physician fee reimbursement for rTHA-A decreased by a mean [and standard deviation] of 27.26% ± 3.57% (from $2,209.11 in 2002 to $1,603.20 in 2019) for femoral component revision, 27.41% ± 3.57% (from $2,130.55 to $1,542.91) for acetabular component revision, and 27.50% ± 2.56% (from $2,775.53 to $2,007.61) for both-component revision. Similarly, for a 2-stage rTHA-I, the mean reimbursement declined by 18.74% ± 3.87% (from $2,063.36 in 2002 to $1,673.36 in 2019) and 24.45% ± 3.69% (from $2,328.79 to $1,755.45) for the explantation and reimplantation stages, respectively. The total decline in physician fee reimbursement for rTHA-I ($1,020.64 ± $233.72) was significantly greater than that for rTHA-A ($580.72 ± $107.22; p < 0.00001). CONCLUSIONS: Our study demonstrated a consistent devaluation of both rTHA-I and rTHA-A procedures from 2002 to 2019, with a larger deficit seen for rTHA-I. A continuation of this trend could create substantial disincentives for physicians to perform such procedures and limit access to care at the population level. LEVEL OF EVIDENCE: Economic and Decision Analysis Level IV. See Instructions for Authors for a complete description of levels of evidence.
引用
- Acuña AJ, Jella TK, Samuel LT, et al. Inflation-Adjusted Medicare Reimbursement for Revision Hip Arthroplasty: Study Showing Significant Decrease from 2002 to 2019. J Bone Joint Surg Am. 2021. PMID: 33764932. doi:10.2106/JBJS.20.01643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。